CRIS Current Research Information System

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.942
EU - Europa 1.762
AS - Asia 1.684
AF - Africa 144
SA - Sud America 110
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.648
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.915
SG - Singapore 560
GB - Regno Unito 468
CN - Cina 434
VN - Vietnam 382
SE - Svezia 328
DE - Germania 223
IT - Italia 215
HK - Hong Kong 113
IN - India 104
RU - Federazione Russa 98
IE - Irlanda 82
FR - Francia 78
BR - Brasile 77
NL - Olanda 43
CI - Costa d'Avorio 42
EE - Estonia 38
UA - Ucraina 38
ZA - Sudafrica 38
FI - Finlandia 36
TG - Togo 33
CH - Svizzera 28
BG - Bulgaria 25
BE - Belgio 22
KR - Corea 21
JO - Giordania 17
CA - Canada 15
NG - Nigeria 14
JP - Giappone 13
AR - Argentina 11
GR - Grecia 10
EC - Ecuador 9
IR - Iran 8
MX - Messico 8
PL - Polonia 8
AT - Austria 7
TR - Turchia 7
ID - Indonesia 6
SC - Seychelles 5
AU - Australia 4
BD - Bangladesh 4
CO - Colombia 4
MA - Marocco 4
CZ - Repubblica Ceca 3
DZ - Algeria 3
EG - Egitto 3
ES - Italia 3
PE - Perù 3
RO - Romania 3
GT - Guatemala 2
IQ - Iraq 2
LT - Lituania 2
MY - Malesia 2
PH - Filippine 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
EU - Europa 1
KE - Kenya 1
LB - Libano 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
Totale 6.648
Salva come PNG Salva come JPEG
Città #
Southend 416
Fairfield 397
Singapore 367
Ashburn 315
Chandler 253
Dong Ket 205
Seattle 184
Woodbridge 168
Houston 161
Cambridge 156
Wilmington 143
Ann Arbor 137
Hong Kong 109
Princeton 92
Dublin 82
Santa Clara 82
Beijing 74
Boardman 55
Nanjing 44
Abidjan 42
Westminster 42
Hefei 41
Bologna 38
Los Angeles 37
Padova 37
Lomé 33
Bremen 32
Ho Chi Minh City 32
Jinan 31
Helsinki 30
New York 30
Hanoi 28
Berlin 25
Bern 25
Sofia 25
Shenyang 24
Brussels 22
Dallas 21
Saint Petersburg 20
Seoul 20
Munich 18
Amman 17
Buffalo 17
Milan 17
Redondo Beach 16
San Diego 16
Turin 16
Frankfurt am Main 15
Abeokuta 13
Falls Church 13
Tokyo 13
Changsha 11
Chicago 11
Hyderabad 11
Jacksonville 11
Zhengzhou 11
Dearborn 10
Hebei 10
London 9
São Paulo 9
Tianjin 9
Guangzhou 8
Nanchang 8
Norwalk 8
Redmond 8
Brooklyn 7
Florence 7
Hangzhou 7
Olalla 7
Orem 7
Paris 7
Phoenix 7
Redwood City 7
Boston 6
Fremont 6
Columbus 5
Des Moines 5
Falkenstein 5
Haikou 5
Istanbul 5
Kyiv 5
Ningbo 5
Taiyuan 5
Turku 5
Bengaluru 4
Biên Hòa 4
Farra d'Isonzo 4
Fuzhou 4
Harbin 4
Jakarta 4
Jiaxing 4
Kunming 4
Medford 4
Mountain View 4
Plauen 4
Quận Bình Thạnh 4
Shanghai 4
Stockholm 4
The Dalles 4
Wenzhou 4
Totale 4.557
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 228
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 226
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 203
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 201
A case report of acute myeloid leukemia and neurofibromatosis 1 199
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 197
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 187
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 187
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 187
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 177
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 172
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 169
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 165
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 164
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 159
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 158
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 154
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 152
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 150
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 148
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 148
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 148
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 144
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 144
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly 143
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 129
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 125
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years 123
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 120
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 119
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 116
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 114
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 113
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 111
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 111
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors 110
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 108
The CD47 pathway is deregulated in human immune thrombocytopenia 103
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 102
null 98
null 96
null 86
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 85
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 67
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 66
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 66
Totale 6.793
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.917
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.917
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021565 0 0 0 0 0 19 23 37 77 51 32 326
2021/2022945 75 36 45 113 87 47 29 46 39 114 169 145
2022/20231.027 109 164 63 144 54 81 31 63 176 42 53 47
2023/2024246 14 42 28 29 20 58 4 10 6 16 8 11
2024/2025904 46 166 82 84 122 37 56 26 25 69 36 155
2025/20261.005 175 149 189 144 212 136 0 0 0 0 0 0
Totale 6.793